Ascelia Pharma AB (publ) (ACE.ST)
SEK 3.6
(10.43%)
SEK 3.6
(10.43%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 176 Thousand SEK | -8.81% |
| 2022 | 193 Thousand SEK | -65.1% |
| 2021 | 553 Thousand SEK | -42.15% |
| 2020 | 956 Thousand SEK | 895.83% |
| 2019 | 96 Thousand SEK | -34.25% |
| 2018 | 146 Thousand SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 17.95 Million SEK | 0.0% |
| 2024 Q2 | 33.44 Million SEK | 86.23% |
| 2023 Q2 | 610 Thousand SEK | -28.65% |
| 2023 FY | 176 Thousand SEK | -8.81% |
| 2023 Q4 | 176 Thousand SEK | -53.81% |
| 2023 Q3 | 381 Thousand SEK | -37.54% |
| 2023 Q1 | 855 Thousand SEK | 343.01% |
| 2022 FY | 193 Thousand SEK | -65.1% |
| 2022 Q4 | 193 Thousand SEK | -19.58% |
| 2022 Q3 | 240 Thousand SEK | 17.65% |
| 2022 Q2 | 204 Thousand SEK | -23.88% |
| 2022 Q1 | 268 Thousand SEK | -51.54% |
| 2021 Q2 | 1.09 Million SEK | 45.29% |
| 2021 Q1 | 753 Thousand SEK | -21.23% |
| 2021 Q3 | 822 Thousand SEK | -24.86% |
| 2021 Q4 | 553 Thousand SEK | -32.73% |
| 2021 FY | 553 Thousand SEK | -42.15% |
| 2020 FY | 956 Thousand SEK | 895.83% |
| 2020 Q2 | 1.17 Million SEK | -13.52% |
| 2020 Q1 | 1.36 Million SEK | 1317.71% |
| 2020 Q3 | 992 Thousand SEK | -15.72% |
| 2020 Q4 | 956 Thousand SEK | -3.63% |
| 2019 Q4 | 96 Thousand SEK | -17.24% |
| 2019 FY | 96 Thousand SEK | -34.25% |
| 2019 Q2 | 146 Thousand SEK | 0.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 Q3 | 116 Thousand SEK | -20.55% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 FY | 146 Thousand SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |